کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8528670 | 1558109 | 2018 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Peripheral artery disease and antiplatelet treatment
ترجمه فارسی عنوان
بیماری عروق محیطی و درمان آنتی بادی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
علوم اعصاب سلولی و مولکولی
چکیده انگلیسی
Peripheral artery disease (PAD) is one of the most important causes of cardiovascular morbidity and mortality and its prevalence is alarmingly increasing in modern societies. PAD shares common characteristics with the other atherosclerotic diseases but involves specifically the arteries of the lower extremities. Apart from the changes in lifestyle, antiplatelet agents are the hallmark of the treatment and improve the symptoms as well as the progression of the disease. Aspirin is the cornerstone of treatment and is administrated in doses ranging from 75 to 325Â mg daily. Additionally, cilostazol and clopidogrel have an important therapeutic role too. Novel antiplatelet agents are the subject of research in both experimental and clinical studies in order to evaluate the efficacy and safety profile. The most important antiplatelet factors which are under investigation are the novel P2Y12 receptor inhibitors prasugrel and ticagrelor. Furthermore, vorapaxar, a protease-activated receptor inhibitor, exhibits antiplatelet properties and has been studied in PAD.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Current Opinion in Pharmacology - Volume 39, April 2018, Pages 43-52
Journal: Current Opinion in Pharmacology - Volume 39, April 2018, Pages 43-52
نویسندگان
Vasiliki Tsigkou, Gerasimos Siasos, Kleanthis Rovos, Niki Tripyla, Dimitris Tousoulis,